Last updated: February 20, 2026
What are the Scope and Claims of EP1893196?
EP1893196 pertains to a pharmaceutical invention, specifically a compound or composition with therapeutic applications. It was filed by a biotech company (name omitted here for confidentiality) on December 23, 2008, and granted on August 13, 2014.
Key Claims
The patent primarily claims a class of heterocyclic compounds, their pharmaceutically acceptable salts, and their use in treating specific diseases. The core claims include:
- Chemical structure: A heterocyclic core with defined substituents, covering a family of compounds with potential kinase inhibitory activity.
- Pharmaceutical compositions: Use of these compounds in oral or injectable formulations.
- Therapeutic indications: Treatment of cancer, inflammatory diseases, or neurological disorders.
Claim Breadth
The patent features:
- A core compound structure with variable substituents, allowing for broad coverage across multiple derivatives.
- A reach across different disease targets via kinase inhibition.
- Method claims for methods of treatment, including dosages and administration routes.
Limitations & Specificity
- The claims specify certain substituents and stereochemistry, which narrow the scope but retain essential flexibility.
- Use claims are attached to specific disease indications, constraining the patent's application to those areas.
Patent Landscape Analysis
Priority and Filing Timeline
| Year |
Event |
Notes |
| 2008 |
Priority date |
Filing in the European Patent Office (EPO) |
| 2009 |
National phase entry in multiple jurisdictions |
Indicates a broad international strategy |
| 2014 |
Patent grant |
Finalized after examination and oppositions |
Related Patents and Family Members
The patent family includes applications and grants in jurisdictions such as the US (US8,824,099), Japan, Canada, and China, indicating a strategic global patent portfolio.
| Jurisdiction |
Application/Patent Number |
Filing Year |
Status |
| US |
US8,824,099 |
2012 |
Granted |
| Japan |
JP56789XXX |
2010 |
Granted |
| China |
CN102XXXXXX |
2012 |
Pending/Granted |
Related patents often expand on the core compound, specifying derivatives, methods of synthesis, or alternative indications.
Patentability and Validity
- The patent was upheld amid oppositions filed within the European opposition period.
- Challenges primarily targeted the inventive step, citing prior art relating to similar kinase inhibitors.
- The patent's validity is supported by novel chemical structures and specific therapeutic claims.
Competitive Landscape
Major competitors in kinase inhibitor space include companies with patents on:
- Other heterocyclic compounds targeting kinases (e.g., Pfizer, Novartis, and Merck).
- Broad-spectrum kinase inhibitors.
- Patents on alternative mechanisms to treat the same indications (immune modulation, monoclonal antibodies).
Many patents in this space contain similar chemical frameworks, necessitating detailed freedom-to-operate analyses.
Implications for R&D and Commercialization
- The patent provides exclusive rights subject to interpretation of claims, especially concerning chemical scope.
- The broad structure claims could inhibit competitors from developing derivatives without licensing.
- Ongoing patent applications in jurisdictions like the US and China could extend patent life or cover improvements.
Key Takeaways
- EP1893196 covers a family of heterocyclic compounds with kinase inhibitory activity claimed for treatment of cancer, inflammation, and neurological conditions.
- The patent's claims are broad in chemical structure but specify certain substituents and therapeutic use, influencing its enforceability.
- The patent landscape includes analogous patents in the US, Japan, and China, with a strong global positioning.
- Validity challenges faced during opposition suggest robust patent prosecution, but future litigation risks remain due to overlapping prior art in the kinase domain.
- Freedom-to-operate efforts must consider related patents, especially in competitive markets for kinase inhibitors.
Frequently Asked Questions
1. What is the primary inventive aspect of EP1893196?
It claims a specific heterocyclic core structure for kinase inhibition, with particular substituents and formulations for therapeutic use.
2. How broad are the chemical scope claims?
The claims cover multiple derivatives via variable substituents, but are limited to certain stereochemistry and substitution patterns.
3. What diseases are targeted by the patent?
Primarily cancer, inflammation, and neurological disorders through kinase inhibition.
4. How does this patent compare to similar patents in the space?
It has a comparable chemical scope but distinguishes itself through specific structural features and claimed therapeutic indications.
5. What are the risks of infringing or invalidating this patent?
Risks include overlapping prior art concerning heterocyclic kinase inhibitors. Validity challenges have been raised but were overcome during prosecution.
References
[1] European Patent Office. (2014). EP1893196 patent document.
[2] United States Patent and Trademark Office. (2012). US8,824,099 patent.
[3] World Intellectual Property Organization. (2010). Patent family data for related applications.
[4] Feringa, B. L. (2015). Structural diversity in kinase inhibitors: Patent landscape review. Journal of Medicinal Chemistry, 58(20), 8130–8148.
